First-line treatment strategies for elderly patients with metastatic colorectal cancer

Drugs and Aging

Volumn 24, Issue 3, 2007, Pages 223-238

  Meulenbeld, Hielke J ^a   Creemers, Geert Jan ^a  

^a CATHARINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PLACEBO; RALTITREXED;

ACNE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVANCED CANCER; ASTHENIA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG WITHDRAWAL; DRY SKIN; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GERIATRIC PATIENT; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; INTESTINAL BLEEDING; MEDICAL DECISION MAKING; META ANALYSIS; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SKIN FISSURE; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT INDICATION; VOMITING;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM METASTASIS;

EID: 33947385820     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724030-00004     Document Type: Review

References (82)

1. Matasar MJ, Sundararajan V, Grann VR, et al. Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy. Drugs Aging 2004; 2 (2): 113-33
2. Vercelli M, Quaglia A, Casella C, et al. Relative survival in elderly cancer patients in Europe. Eur J Cancer 1998; 34: 2264-70
3. Denduluriand N, Ershler WB. Aging biology and cancer. Semin Oncol 2004; 31: 137-48
4. Lichtman SM. Management of advanced colorectal cancer in older patients. Oncology 2005 Apr; 19 (5): 597-602
5. Muss HB, Longo DL. Introduction: cancer in the elderly. Semin Oncol 2004; 31: 125-7
6. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-7
7. Lichtmann SM. Guidelines for the treatment of elderly cancer patients. Cancer Control 2003; 10 (6): 445-53
8. Monfardini S, Sorio R, Boes GH, et al. Entry and evaluation of elderly patients in European Organization for Research and Treatment of Cancer (EORTC) new-drug-development studies. Cancer 1995; 76: 333-8
9. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-7
10. Kemeny M, Muss HB, Kornblith AB, et al. Barriers to participation of older women with breast cancer in clinical trials [abstract]. Prog Proc Am Soc Clin Oncol 2000; 19: 602a
11. Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer 1994; 74 Suppl. 7: 2208-14
12. Muss HB. Older age: not a barrier to cancer treatment. N Engl J Med 2001; 345 (15): 1128-9
13. Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer 1998; 82: 2123-34
14. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16 (4): 1582-7
15. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-87
16. Simmonds PD, Best L, George S, et al. Surgery for colorectal cancer in elderly patients: a systematic review. Lancet 2000; 356: 968-74
17. Puig-La Calle J Jr, Quayle J, Thaler HT, et al. Favorable short-term and long-term outcome after elective radical rectal cancer resection in patients 75 years of age or older. Dis Colon Rectum 2000; 43 (12): 1704-9
18. Zingmond D, Maggard M, O'Connell J, et al. What predicts serious complications in colorectal cancer resection? Am Surg 2003; 69 (11): 969-74
19. Temple LK, Hsieh L, Wong WD, et al. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 2004 Sep 1; 22 (17): 3475-84
20. Goyle S, Maraveyas A. Chemotherapy for colorectal cancer. Dig Surg 2005; 22: 401-14
21. The Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22: 3766-75
22. Best L, Simmonds P, Baughan C, et al. Palliative chemotherapy for advanced or metastatic colorectal cancer. In: Colorectal Meta-analysis Collaboration. The Cochrane Library. Issue 2. Chichester: John Wiley & Sons, Ltd, 2000: CD001545
23. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-7
24. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47
25. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-14
26. Milburn Jessup J, Stewart A, Greene FL. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age and differentiation. JAMA 2005; 294: 2703-11
27. Popescu RA, Norman A, Ross PJ, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17 (8): 2412-8
28. Köhne CH, Cunningham D, di Costanzo F, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-17
29. Mahoney T, Kuo Y-H, Topilow A, et al. Stage III colon cancer: why adjuvant treatment is not offered to elderly patients. Arch Surg 2000; 135: 182-5
30. Schrag D, Cramer L, Bach P, et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001; 93: 850-7
31. Sundararajan V, Grann V, Neugut A. Population based variation in the use of chemotherapy for colorectal cancer in the elderly [abstract]. Proc Am Soc Clin Oncol 1999; 18: A1598
32. Lichtman SM. Chemotherapy in the elderly. Semin Oncol 2004; 31 (2): 160-74
33. Wasil T, Lichtman SM. Clinical pharmacology issues relevant to the dosing and toxicity of chemotherapy drugs in the elderly. Oncologist 2005; 10: 602-12
34. Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61: 331-9
35. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005; 27 (1): 23-44
36. Takimoto CH, Remick SC, Sharma S, et al. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol 2003; 30: 20-5
37. Jefford M, Zalcberg J. Recent advances in the systemic therapy of metastatic colorectal cancer. Am J Cancer 2005; 4 (1): 15-34
38. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004; 40 (7): 939-50
39. Li HX, Zh S, Zhang YH, et al. Expressions of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase in breast cancer and their correlations with prognosis. Chinese J Oncol 2004; 26 (11): 669-72
40. Li H, Suo Z, Zhang Y, et al. The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas. Histol Histopathol 2004; 19 (1): 129-36
41. The Meta-Analysis Group in Cancer. Colorectal Cancer Meta-Analysis Project: efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-8
42. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001; 19 (8): 2282-92
43. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19 (21): 4097-106
44. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004; 15: 1330-8
45. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006; 24 (15): 2368-75
46. Feliu J, Escudero P, Llosa F, et al. Capecitabine as first line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group Study. J Clin Oncol 2005; 23: 3104-11
47. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-57
48. Golfinopoulos V, Pentheroudakis G, Pavlidis N. Treatment of colorectal cancer in the elderly: a review of the literature. Cancer Treat Rev 2006; 32 (1): 1-8
49. Rougier P, van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-12
50. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-8
51. Köhne CH, Van Cutsem E, Wils JA, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005; 23: 4856-65
52. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-14
53. Rothenberg M, Cox J, DeVore R, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999; 85: 786-95
54. Sastre J, Marcuello E, Masutti B, et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 2005 May 20; 23 (15): 3545-51
55. Mitry E, Douillard JY, van Cutsem E, et al. Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 2004; 15: 1013-7
56. Chau I, Norman AR, Cunningham D, et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 2004; 91: 1453-8
57. Marsh S, McLeod HL. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004 Oct; 5 (7): 835-43
58. de Jong FA, Kehrer DFS, Mathijssen RHJ, et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist 2006; 11 (8): 944-54
59. Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998; 16: 2739-44
60. Raymond E, Emanuel D, Rostagi R, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9: 1053-71
61. Giacchetti S, Perpoint B, Zidane R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-47
62. Exquis B, Aapro M, Kohler S. Oxaliplatin (with 5FU and leucovorin) in patients above age 70 (elderly) suffering from metastatic colorectal cancer: an observational study [abstract 8042]. Proc Am Soc Clin Oncol 2004; 23: 735
63. Cassidy J, Taberno J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-91
64. Feliu J, Salud A, Escudero P, et al. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 2006; 94 (7): 969-75
65. Comella P, Natale D, Farris A, et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal cancer: final results of the Southern Italy Cooperative Oncology Group (SICOG) trial 0108. Cancer 2005; 104: 282-9
66. Sargent DJ, Goldberg RM, Bleiberg H, et al. A pooled safety and efficacy analysis of the FOLFOX4 regimen (bi-monthly oxaliplatin plus fluorouracil/leucovorin) in elderly compared to younger patients with colorectal cancer [abstract no. 228]. In: Program and abstracts of the 2006 Gastrointestinal Cancers Symposium; 2006 Jan 26-28; San Francisco
67. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71: 2454-60
68. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 2004 Jul 22; 351 (4): 337-45
69. Saltz L, Kies M, Abbruzzese JL, et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [abstract]. Prog Proc Am Soc Clin Oncol 2003; 22: 204a
70. Kabbinavar FF, Schulz J, McCleod M, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11 [abstract]. Proc Am Soc Clin Oncol 2004; 23: 3516
71. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 (23): 2335-42
72. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003 Jan 1; 21 (1): 60-5
73. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003 Jul 31; 349 (5): 427-34
74. Maughan T. Fluorouracil, oxaliplatin, CPT-11, use and sequencing, in advanced colorectal cancer: the UK MRC FOCUS (CR08) Trial [abstract no. 165]. In: GI Cancers Symposium; 2005 Jan 27-29; Hollywood (FL)
75. Mattioli R, Lippe P, Recchia F, et al. Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion. Anticancer Res 2001 Jan-Feb; 21 (1A): 489-92
76. Enzinger PC, Mayer RJ. Gastrointestinal cancer in older patients. Semin Oncol 2004; 31 (2): 206-19
77. Mattioli R, Massacesi C, Recchia F, et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005; 16 (7): 1147-51
78. Hamermann D. Toward an understanding of frailty. Ann Intern Med 1999; 130: 945-50
79. Carreca I, Balducci L. Oral chemotherapy for the older patient with cancer. Am J Cancer 2002; 1 (2): 101-8
80. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40 (5): 373-83
81. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998 Apr; 16 (4): 1582-7
82. Balducci L, Beghe C. The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol 2000; 35 (3): 147-54